Pharmacy

Dec 25 2017

Patheon and DSM complete $ merger to form private company DPx #pharmaceutical #industry #marketing

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Dec 18 2017

Patheon and DSM complete $ merger to form private company DPx #pharma #test

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 30 2017

Patheon and DSM complete $ merger to form private company DPx #novartis #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 14 2017

Patheon and DSM complete $ merger to form private company DPx #orbus #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 13 2017

Teva Buys Drug Rival, Barr, for $ Billion #pharmaceuticals #companies

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Nov 12 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #biggest #pharmaceutical #companies

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Aug 25 2017

Patheon and DSM complete $ merger to form private company DPx #dainippon #sumitomo #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Aug 14 2017

Teva Buys Drug Rival, Barr, for $ Billion #qrx #pharma

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Aug 13 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #pharmaceutical #contract #manufacturing

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Jul 31 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #drug #rep #jobs

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Jul 22 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #mcneil #pharma

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

May 28 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #pharma #blog

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

May 12 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #astellas #pharma #europe

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Apr 27 2017

Teva Buys Drug Rival, Barr, for $ Billion #chugai #pharma

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Apr 16 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #mission #pharma

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Mar 31 2017

Patheon and DSM complete $ merger to form private company DPx #pharma #magazine

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Mar 17 2017

Teva Buys Drug Rival, Barr, for $ Billion #pharmacia

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Feb 10 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #cipla #pharma

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Jan 30 2017

Patheon and DSM complete $ merger to form private company DPx #abbott #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Jan 25 2017

Teva Buys Drug Rival, Barr, for $ Billion #health #industry #news

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Jan 21 2017

Amgen soars after bagging Onyx Pharma in $ buyout deal #dsm #pharma

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Dec 9 2016

Patheon and DSM complete $ merger to form private company DPx #gmp #pharma

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Dec 8 2016

Teva Buys Drug Rival, Barr, for $ Billion #cafe #pharma #boards

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Nov 21 2016

Patheon and DSM complete $ merger to form private company DPx #cipla

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 21 2016

Teva Buys Drug Rival, Barr, for $ Billion #juventus #pharma

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Nov 20 2016

Amgen soars after bagging Onyx Pharma in $ buyout deal #pharmaceutical #companies #usa

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Nov 11 2016

Teva Buys Drug Rival, Barr, for $ Billion #pharma #r&d

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Nov 3 2016

Patheon and DSM complete $ merger to form private company DPx #pharma #agency

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Nov 1 2016

Amgen soars after bagging Onyx Pharma in $ buyout deal #fosun #pharma

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Oct 26 2016

Amgen soars after bagging Onyx Pharma in $ buyout deal #gw #pharma

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Oct 4 2016

Teva Buys Drug Rival, Barr, for $ Billion #pharma #pipeline

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Oct 4 2016

Amgen soars after bagging Onyx Pharma in $ buyout deal #pharma #info

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Sep 26 2016

Patheon and DSM complete $ merger to form private company DPx

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Sep 26 2016

Teva Buys Drug Rival, Barr, for $ Billion

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …

Sep 25 2016

Amgen soars after bagging Onyx Pharma in $ buyout deal

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …

Sep 17 2016

Patheon and DSM complete $ merger to form private company DPx

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …

Sep 15 2016

Amgen soars after bagging Onyx Pharma in $ buyout deal

#onyx pharma # Amgen soars after bagging Onyx Pharma in $10.4B buyout deal Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder at the table. After starting out with an unsolicited $120-a-share offer for Onyx ($ONXX), the giant biopharma company settled on a final price of $125 a share–all of it to be paid in cash–valuing Onyx at $10.4 billion, or $9.7 billion net of cash. News of the impending buyout had been percolating all weekend long after The New York Times first reported …